FDA - ALTHOUGH NOT AN FDA REQUIREMENT, GSK HAS COMMITTED TO ASSE…

FDA - ALTHOUGH NOT AN FDA REQUIREMENT, GSK HAS COMMITTED TO ASSESS ATRIAL FIBRILLATION IN THE POSTMARKETING STUDY RELATED TO AREXVY
... | May 3, 2023

Related Keywords

,Gsk Plc Stock Exchange ,News ,Information ,Press Release ,Fda ,Although ,Lot ,N ,Mask ,Gas ,Ommitted ,O ,Ssess ,Trial ,Defibrillation ,The ,Ostmarketing ,Study ,Elated ,O Gsk Gb00bn7swp63 ,